C-PTBE-01

Indicaton

C-PTBE-01 has shown a strong steroid-sparing effect in two clinical safety and efficacy studies in patients with brain tumors and peritumoral brain edema (PTBE). C-PTBE-01 can lead to a market reduction or complete replacement of steroid use. This can alleviate the severe steroid-induced side effects and thus improve the quality of life of those affected.

Therapeutic indications

Oncology

Type of product

Peptide

Table

Phase

Phase II completed
Partnering status

Not partnered
Available in

Global

You may also be interested in

Breast cancer screening test

Xemperia flag-ship project is a PCR-based blood test for breast cancer screening. The technology can be adapted to other cancers, immune, inflammatory and cardiovascular diseases. Xemperia's pipeline also includes DNA based nansensors for the ultrasensitive detection of nucleic acids.

Phase II completed

OligoPhore / SemaPhore / CycloPhore Peptide-Based RNA Delivery Platforms

Delivers siRNA, antisense oligonucleotides, linear or circular mRNA and other RNA modalities to extrahepatic tissues - demonstrated across various indications in oncology (e.g. PDAC, breast cancer, ovarian cancer, lung cancer, melanoma, ATLL, TME), and inflammatory / autoimmune diseases (e.g. OA, RA, enterocolitis), CV (e.g. atherosclerosis, aortic aneurysm)

Discovery

SOT201 (Immunocytokine, PD-1 x IL-15)

solid tumors

Phase I started